Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

Cellectis S.A.. (12/8/11). "Press Release: Cellectis Bioresearch and Syngene Announce Partnership on the Development of Customized Cell Lines". Paris & Bangalore.

Organisations Organisation Cellectis Bioresearch S.A.S.
  Group Cellectis (Group)
  Organisation 2 Syngene International Ltd.
  Group Biocon (Group)
Products Product cell line development (research assays)
  Product 2 Meganuclease technology (Cellectis)
Index term Index term Biocon–Cellectis: cell line development, 201112– collab developm genetically customised cell linces Syngene Intl + Cellectis Bioresearch
Persons Person Le Bozec, Marc (Cytoo 201305– CEO + France Biotech Board Member before Cellectis 2006–201302 CFO LEFT 2/13)
  Person 2 Bains, Peter (Sosei 201603– COO + CEO-select before Biocon/Syngene International + GSK)

Cellectis bioresearch, the specialist in genome customization and commercial subsidiary of Cellectis (Alternext: ALCLS), and Syngene International Ltd, an internationally reputed contract research and manufacturing services (CRAMS) organization and subsidiary of BIOCON Ltd, India's largest biotechnology company by revenue, announced today that they have entered into an agreement to develop novel genetically customized cell lines.

This partnership between Cellectis bioresearch and Syngene will leverage Cellectis' patented technology in genome customization with Syngene's strong biology platform and capabilities to develop novel recombinant and knock-out cell lines for use in oncology- and ADME-Tox-based drug discovery studies.

"This new partnership with Syngene International will enable us to mobilize each organization's expertise and know-how and create synergies that will deliver hundreds of engineered cell lines for drug discovery and functional genomics" said Marc Le Bozec, Chief Executive Officer, Cellectis bioresearch.

Peter Bains, Chief Operating Officer, Syngene International said, "We are very pleased to enter into this strategic collaboration with Cellectis bioresearch. This is a very exciting R&D arena, employing state-of-the-art technologies, and we are delighted to have the opportunity to support Cellectis' goals through our biology platform at Syngene.''

About Cellectis bioresearch

Established in 2008 as a subsidiary of Cellectis, Cellectis bioresearch provides life sciences researchers with genome customization tools and services, such as the award-winning TALEN® Access™. The company also develops and markets genetically customized cells with characteristics and performances adapted to three main markets: drug discovery, gene function studies and protein production.

For further information, please visit

About Syngene International Limited

Established in 1994 as a subsidiary of Biocon Limited, Syngene is an internationally reputed custom research and manufacturing company with multi-disciplinary skills in integrated drug discovery and development, with capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&D and formulation development for both small and large molecules. Over the past 16+ years, Syngene has successfully partnered with leading players in the global pharmaceutical industry offering its services across drug discovery/ development continuum. Syngene has over 1500 scientists and is well-equipped to offer its world class services to its customers from early stage discovery and preclinical development through clinical development (Phase I-III) till commercial manufacturing requirements for small and large molecules in the most efficient manner in terms of cost, quality and time.

For further information, please visit

For further information, please contact

Philippe Valachs
Company Secretary
Tel: +33 (0)1 81 69 16 00

Alexis Breton / Cyril Combe
+33 (0)1 53 65 68 68

Record changed: 2019-06-09


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Cellectis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px

» top